SAN CARLOS, Calif.--(BUSINESS WIRE)--Jan. 3, 2006--NeurogesX, Inc., a privately held specialty pharmaceutical company focused on the development and commercialization of novel treatments for relief of neuropathic pain, today announced that Jeffrey Tobias, M.D., has joined the company as chief medical officer. Dr. Tobias will be responsible for all clinical development activities, including Transacin(TM), NeurogesX's proprietary dermal patch for the treatment of neuropathic pain.
